News & Events about Acorda Therapeutics Inc.
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1, 2022 press release announcing its financial results for the third quarter of 2022. The revised guidance corrects certain errors...
Business Wire
2 months ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Companys stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders. We are grateful to our shareholders who supported this proposal at a ratio of almost two and a half to one...
Business Wire
3 months ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) convened its Special Meeting of Stockholders on November 4, 2022, and a proposal to adjourn the meeting was approved in order to provide stockholders with additional time to vote on Proposal Two, Reverse Stock Split. The Special Meeting will be reconvened on...
Business Wire
3 months ago
Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET, 10:00am PT. The call will review the items on the ballot for Acordas Special Meeting of Shareholders on November 4, 2022. Participants will be able to...
Thinking about buying stock in Federated National, Acorda Therapeutics, Nio, Avenue Therapeutics, or Visa? Thinking about buying stock in Federated National, Acorda Therapeutics, Nio, Avenue Therapeutics, or Visa? PR Newswire NEW YORK, Oct. 17, 2022 NEW YORK, Oct. 17, 2022 /PRNewswire...